CCS1477

First-in-class p300/CBP inhibitor to treat specific cancers

  • 50+

    Epigenetic-related targets

    investigated over time by the CellCentric team

  • 1

    Drug prioritised, advanced

    CCS1477 in the clinic, to treat specific cancers

The target

CCS1477 is the first small molecule drug targeting twin proteins p300 and CBP. It is a small molecule, formulated as a capsule taken orally, in Phase I/II clinical trials.

p300/CBP are twin (paralogue) acetyl transferases and gene activating proteins that are known to play an important role in the progression of certain cancers.

CCS1477 is a novel drug which inhibits p300/CBP by binding to the twin proteins’ conserved bromodomain. This impacts the growth of specific types of cancer.

CellCentric’s pioneering drug is in clinical trials to evaluate its effectiveness to treat late stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers (over-expressing AR or MYC; or with a p300 or CBP mutation). These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives.

Tweets by @cellcentric

Follow us

Delighted to announce $33m of further funding; continuing to progress our first-in-class p300/CBP inhibitor CCS1477, in clinical trials for multiple cancer applications. pic.twitter.com/pzxlzz2mmd

Neil and Nigel (virtually) at the always excellent Prostate Cancer Foundation Retreat over the next 3 days. pic.twitter.com/NjVknIyWW0

Great to have another site open as we expand clinical testing of our first-in-class p300/CBP inhibitor. Edinburgh; haem malignancies. pic.twitter.com/HfC6vJsy4A